Sandbox fungal meningitis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m Bot: Automated text replacement (-Category:Primary care +) |
||
(7 intermediate revisions by 2 users not shown) | |||
Line 196: | Line 196: | ||
===Angiostrongyliasis=== | ===Angiostrongyliasis=== | ||
{| | |||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Angiostrongyliasis]]}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]] 60 kg or greater: 400 mg twice daily PO with | |||
meals<BR>''OR''<BR> less than 60 kg:7.5 mg/kg PO bid with meals (maximum total daily dose 800 mg)''''' | |||
|- | |||
|} | |||
|} | |||
===Amebic meningoencephalitis=== | |||
{| | {| | ||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Amebic meningoencephalitis]]}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Miltefosine]]''''' | |||
|- | |||
|} | |||
|} | |||
===Eosinophilic myeloencephalitis, Meningitis=== | |||
{| | |||
|- | |- | ||
| valign=top | | | valign=top | | ||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | {| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[ | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Eosinophilic myeloencephalitis, Meningitis]]}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]''''' | |||
|- | |||
|} | |||
|} | |||
===Toxoplasma gondii, Meningitis=== | |||
{| | |||
|- | |||
| valign=top | | |||
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:39em" cellpadding="0" cellspacing="0"; | |||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Toxoplasma gondii, Meningitis]]}}'' | |||
|- | |||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen'' | |||
|- | |||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[albendazole]]''''' | ||
|- | |- | ||
Line 213: | Line 256: | ||
|} | |} | ||
==M. tuberculosis Meningitis <SMALL><SMALL><SMALL><SMALL><SMALL>Adapted from Treatment of Tuberculosis guidelines<ref>{{Cite web | last = | first = | title = http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1 | url = http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1 | publisher = | date = | accessdate = 22 January 2014 }}</ref></SMALL></SMALL></SMALL></SMALL></SMALL>== | |||
==M. tuberculosis Meningitis== | |||
{| | {| | ||
|- | |- | ||
Line 222: | Line 264: | ||
|-! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Intensive Phase(for 9-12 mo)'' | |-! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Intensive Phase(for 9-12 mo)'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO max: 600mg''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO daily max: 600mg<BR> ''OR''<BR> 8-12mg/kg/day PO 3 times per week x:600mg''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO max: 300mg''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO daily max: 300mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:900mg''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 20-30 mg/kg/day PO''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Pyrazinamide]] 20-30 mg/kg/day PO<BR>''OR''<BR> 30-40mg/kg/day PO 3 times per week''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Streptomycin]] 12-18 mg/kg/day PO''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Streptomycin]] 12-18 mg/kg/day IM<BR>''OR''<BR> 25-35mg/kg/day PO 3 times per week daily max:1000mg''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Continuation Phase'' | ! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Continuation Phase'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO max: 600mg''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Rifampicin]] 8-12 mg/kg/day PO daily max: 600mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:600mg''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''PLUS'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO max: 300mg''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Isoniazid]] 4-6 mg/kg/day PO daily max: 300mg<BR>''OR''<BR> 8-12mg/kg/day PO 3 times per week daily max:900mg''''' | ||
|- | |- | ||
|} | |} | ||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] |
Latest revision as of 06:37, 28 July 2020
Meningitis Main Page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Sheng Shi, M.D. [2]
fungal meningitis
Blastomyces
|
Candidiasis
|
Histoplasma
|
Coccidioides[1]
|
Cryptococcus HIV/AIDS[2]
|
Cryptococcus Immunocompetent[3]
|
Viral Meningitis[4]
|
Parasitic Meningitis
Angiostrongyliasis
|
Amebic meningoencephalitis
|
Eosinophilic myeloencephalitis, Meningitis
|
Toxoplasma gondii, Meningitis
|
M. tuberculosis Meningitis Adapted from Treatment of Tuberculosis guidelines[5]
|
References
- ↑ Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA et al. (2005) Coccidioidomycosis. Clin Infect Dis 41 (9):1217-23. DOI:10.1086/496991 PMID: 16206093
- ↑ Antinori S (2013) New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS 2013 ():471363.http://dx.doi.org/10.1155/2013/471363 DOI:10.1155/2013/471363] PMID: 24052889
- ↑ Jackson A, van der Horst C (2012) New insights in the prevention, diagnosis, and treatment of cryptococcal meningitis. Curr HIV/AIDS Rep 9 (3):267-77. DOI:10.1007/s11904-012-0127-7 PMID: 22763808
- ↑ Studahl M, Lindquist L, Eriksson BM, Günther G, Bengner M, Franzen-Röhl E et al. (2013) Acute viral infections of the central nervous system in immunocompetent adults: diagnosis and management. Drugs 73 (2):131-58. DOI:10.1007/s40265-013-0007-5 PMID: 23377760
- ↑ "http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdf?ua=1" (PDF). Retrieved 22 January 2014. External link in
|title=
(help)